First-gen drugs feature in BCL-2 combos, while Jaypirca and BTK degraders apply extra pressure.
ApexOnco Front Page
Recent articles
A year after paying $55m to license Biotheus’s PD-L1/VEGF, BioNTech is going all in for $800m.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Patients' expression of CEACAM5 might hold the key to activity after all.
Spectrum’s poziotinib failed in HER2 exon 20 lung cancer, but that isn’t stopping Boehringer and Bayer.
The group is going beyond EGFR exon 20 insertions, but still has work to do to justify its valuation.
